Rise Nano Optics to Attend the 2026 Cantech Investment Conference in Toronto
Vancouver, British Columbia--(Newsfile Corp. - October 1, 2026) - Rise Nano Optics Ltd. (CSE: EYE) (OTCQB: RNOLF) (FSE: U9Y) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, is pleased to announce that members of its management team will attend the 2026 Cantech Investment Conference on October 8, 2026, in Toronto, Ontario. The Cantech Investment Conference is one of Canada's lead
2026-10-01 7:00 AM EDT | Rise Nano Optics Ltd.
Promino TikTok Creator Content More Than Triples as Network Scales in First Full Quarter
Burlington, Ontario--(Newsfile Corp. - October 1, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company") today reported operating results from its first full quarter on TikTok Shop USA, covering the period from July 1 through September 30, 2026. During the quarter, Promino: contacted more than 30,000 TikTok creators; approved more than 2,500 creators for its Rejuvenate Muscle Health™ program;
Food / Beverages, Sports, Health
2026-10-01 7:00 AM EDT | Promino Nutritional Sciences, Inc.
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to announce its participation in the 17th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California. World ADC San Diego is a leading global foru
Biotechnology, Pharmaceuticals, Health
2026-10-01 3:15 AM EDT | Defence Therapeutics Inc.
TempraMed Technologies Ltd. Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - September 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), is pleased to announce that, further to its September 23, 2026 and September 28, 2026 news releases, it has closed its non-brokered private placement (the "Offering") of unsecured convertible debentures of the Company (each, a "Convertible Debenture") and units (each, a "Unit"). The Company issued $600,000 of principal amount of C
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-30 6:00 PM EDT | TempraMed Technologies Ltd.
Tersis Technologies Files U.S. Provisional Patent Application to Turn Waste-Derived Carbon into Energy-Storage Material
Miami, Florida--(Newsfile Corp. - September 30, 2026) - Tersis Technologies, Inc. (OTCID: TERS) ("Tersis" or the "Company"), a clean technology company advancing waste-to-value and circular infrastructure solutions, today announced that it has filed a U.S. provisional patent application with the United States Patent and Trademark Office covering a process to convert waste-derived carbon into a graphenic material intended for energy storage. The application, titled "Hook-Morphology Graphenic C
Agriculture, Energy, Alternative Energy, Health
2026-09-30 9:30 AM EDT | Tersis Technologies Inc.
Edison Issues Report on Starpharma (SPL)
London, United Kingdom--(Newsfile Corp. - September 30, 2026) - Edison issues report on Starpharma (ASX: SPL) Starpharma is a biotechnology company specialised in targeted oncology, underpinned by its proprietary, clinically established dendrimer enhanced product (DEP) platform. The investment case combines two approaches to value creation: retaining more favourable economics through internally developed targeted oncology assets, while partnered programmes broaden DEP's reach, validate
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-09-30 4:23 AM EDT | Edison Group
BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, today announced that its upcoming Annual General Meeting ("AGM"), originally scheduled for October 14, 2026, has been rescheduled and reclassified as an Annual General and Special Meeting ("AGSM"). The rescheduled meeti
2026-09-29 5:59 PM EDT | BetterLife Pharma Inc.
Altrova Health Closes Debt Settlement
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to announce that it has closed a debt settlement involving the issuance of common shares in settlement of C$215,000 of bona fide indebtedness (the "Debt Settlement"). All dollar amounts in this news release are expressed in Canadian dollars unless otherwise indicated. The Debt Settlement did not result in
2026-09-29 5:02 PM EDT | Altrova Health Inc.
WELL Health Subsidiary WELLSTAR Announces Completion of Amalgamation and Expected Trading Date of "WSTR" on TSXV
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its subsidiary, WELLSTAR Technologies Corp. ("WELLSTAR") has completed the previously announced amalgamation (the "Transaction") with 1587818 B.C. L
Technology, Computer Software, Healthcare and Hospitals, Health
2026-09-29 3:30 PM EDT | WELL Health Technologies Corp.
At the Longevity Investors Conference in Gstaad, Investors Test Which Longevity Claims Hold Up
Zug, Switzerland--(Newsfile Corp. - September 29, 2026) - As longevity research moves from animal models into human trials, investors are asking a sharper question: what is science, and what is hype? That question shaped the seventh Longevity Investors Conference (LIC), held from 14 to 17 September 2026 at Le Grand Bellevue in Gstaad.
2026-09-29 11:46 AM EDT | Longevity Investors AG
Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line
Winter Park, Florida--(Newsfile Corp. - September 29, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that its laboratory subsidiary, Adia Labs LLC, has expanded its product portfolio with three new research-use offerings: Adia30M, AdiaClear, and AdiaEXO.
Healthcare and Hospitals, Health
2026-09-29 8:00 AM EDT | Adia Med Inc.
Ian Mortimer Receives the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, as the recipient of the 2026 Bloom Burton Award.
Technology, Biotechnology, Investment Banking, Health
2026-09-29 8:00 AM EDT | Bloom Burton & Co. Inc.
Edison Issues Report on iQSTEL (IQST)
London, United Kingdom--(Newsfile Corp. - September 29, 2026) - Edison issues report on iQSTEL (NASDAQ: IQST). iQSTEL has built a global telecommunications platform providing international voice and data termination services. The company has yet to achieve profitability and has had to rely on dilutive equity funding. Over the last decade, iQSTEL has grown rapidly through acquisitions and organic expansion to its current revenue run rate of over $0.5bn. Via commercial agreements with mor
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-09-29 7:53 AM EDT | Edison Group
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsid
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-29 7:53 AM EDT | Rhelion Life Sciences Corp.
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Key Highlights Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-29 7:30 AM EDT | KALA Bio Inc.
BioHarvest Sciences Announces Share Repurchase Program
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in acc
Biotechnology, Pharmaceuticals, Health
2026-09-29 7:00 AM EDT | BioHarvest Sciences Inc.
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee. Sherry Aulin is a f
Biotechnology, Pharmaceuticals, Health
2026-09-29 3:15 AM EDT | Defence Therapeutics Inc.
TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus
Highlights: LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum combined unit commitment will be nego
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-29 3:05 AM EDT | TempraMed Technologies Ltd.
TempraMed Announces Upsize to Offering
Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-brokered private placement (the "Offering") previously announced on Wednesday, September 23, 2026. The Upsized Offering wil
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-28 5:49 PM EDT | TempraMed Technologies Ltd.
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 20,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.03 per Unit for gross proceeds of up to $600,000. Each Unit consists of one (1) common share of the Company (each, a "Shar
Biotechnology, Pharmaceuticals, Health
2026-09-28 5:00 PM EDT | PreveCeutical Medical Inc.